Chokyu Isao, Ishibashi Kenichi, Goto Takeo, Ohata Kenji
Department of Neurosurgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
J Med Case Rep. 2012 Jul 2;6:181. doi: 10.1186/1752-1947-6-181.
Tumor-induced osteomalacia is a paraneoplastic syndrome of hypophosphatemia. Osteomalacia causes multiple bone fractures and severe pain.
We report the case of a 57-year-old Japanese man with tumor-induced osteomalacia associated with a middle cranial fossa bone tumor. The tumor was successfully resected by using a middle fossa epidural approach. His phosphate level recovered to a normal range immediately after the surgery.
It is rare that tumor-induced osteomalacia originates from the middle skull base. This report suggests that, if patients have a clinical and biochemical picture suggestive of tumor-induced osteomalacia, it is crucial to perform a meticulous examination to detect the tumor or the lesion responsible for the tumor. The serum level of fibroblast growth factor 23 is the most reliable marker for evaluating the treatment outcome of tumor-induced osteomalacia.
肿瘤诱导的骨软化症是一种伴有低磷血症的副肿瘤综合征。骨软化症会导致多处骨折和剧痛。
我们报告一例57岁日本男性患者，其患有与中颅窝骨肿瘤相关的肿瘤诱导的骨软化症。通过中颅窝硬膜外入路成功切除了肿瘤。术后他的磷酸盐水平立即恢复到正常范围。
肿瘤诱导的骨软化症起源于中颅底的情况较为罕见。本报告表明，如果患者具有提示肿瘤诱导的骨软化症的临床和生化表现，进行细致检查以检测肿瘤或导致该肿瘤的病变至关重要。成纤维细胞生长因子23的血清水平是评估肿瘤诱导的骨软化症治疗效果最可靠的标志物。
